{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-344572","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2026-08-11T20:04:43+00:00","discovered_at":"2026-08-11T20:06:00.542478+00:00","generated_at":"2026-08-11T20:06:26.994311+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kyverna Q2: net loss $38.3M ($0.63/share); RMAT for miv-cel in naSPMS; SPS BLA on track for Q4 2026","bullets":["Cash, equivalents and marketable securities $199.4M at June 30, 2026; operating runway into 2028.","Q2 2026 R&D expenses $24.8M; G&A expenses $14.8M; net loss $38.3M or $0.63 per share.","FDA granted RMAT designation for miv-cel in non-active secondary progressive MS (naSPMS) based on IIT data from Stanford and UCSF.","Rolling BLA for miv-cel in stiff person syndrome underway; CMC module submitted; completion targeted Q4 2026 with priority review and potential 2027 launch.","KYSA-6 Phase 3 gMG enrollment expected complete mid-2027; KYSA-8 12-month and Phase 2 gMG follow-up topline data expected Q3 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-344572","json":"https://secwatch.observer/filing/0001193125-26-344572.json","markdown":"https://secwatch.observer/filing/0001193125-26-344572.md","text":"https://secwatch.observer/filing/0001193125-26-344572.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526344572/0001193125-26-344572-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526344572/kytx-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T20:06:26.994311+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}